Adverse Reactions of Lianhua Qingwen Capsules/Granules: A Systematic Review and Meta-analysis

doi:10.19803/j.1672-8629.2021.09.14

Abstract

Abstract: Objective To systematically assess the reporting rate and characteristics of adverse drug reactions (ADR) during clinical use of Lianhua Qingwen capsules/granules. Methods The CNKI, Wanfang platform, CQVIP, SinoMed and PubMed, Embase and the Cochrane library were searched systematically for related literature that had been published by July 7, 2020. The quality of literature was evaluated using the recommendations of Cochrane ADR method group in order to assess the quality elements of injury evidence. Meta-analysis was carried out with STATA software. Results A total of 12 039 patients were included in this study, and 531 cases of ADR were reported, so the total reporting rate of ADR was 2.37% (95%CI: 1.64%~3.21%). The reporting rate of ADR increased with time, especially in the RCT study. The main manifestations of ADR were gastrointestinal system damage (361 cases/67.98%), nervous system damage (36 cases/6.78%) and skin and its appendages damage (29 cases/5.46%). Combined medications (2.79%) had a higher reporting rate of ADR than the single use (1.92%). Conclusion To reduce the cases of ADR, the monitoring of clinical use of Lianhua Qingwen should be strengthened.

Key words: Lianhua Qingwen capsules, Lianhua Qingwen granules, adverse drug reaction, systematic review, meta-analysis

CLC Number:

R994.11

LIU Bo, WANG Xue, GUAN Shaochen, AN Moran, MU Yajie, YU Haixia, LI Yonglin, ZHANG Yatong. Adverse Reactions of Lianhua Qingwen Capsules/Granules: A Systematic Review and Meta-analysis[J]. Chinese Journal of Pharmacovigilance, 2021, 18(9): 864-868.

References

[1] Zhou XP.Research progress on the efficacy and clinical application of Lianhua Qingwen Capsule (LHQW)[J]. Information on Traditional Chinese Medicine(中医药信息), 2016,33(1):107-111.
[2] Yang M, Yang SH, Yang M, et al.Systematic review on the treatment of novel coronavirus pneumonia with Chinese herbal Lianhua Qingwen[J]. Chinese Journal of Drug Evaluation(中国药物评价), 2020,37(2):126-130.
[3] Ling XY, Tao JL, Sun X, et al.Exploring material basis and mechanism of Lianhua Qingwen prescription against coronavirus based on network pharmacology[J]. Chinese Traditional and Herbal Drugs(中草药), 2020, 51(7): 1723-1730.
[4] Hu YF.Analysis of pharmacology and clinical efficacy of Lianhua Qingwen capsule[J]. Modern Diagnosis and Treatment(现代诊断与治疗), 2013, 24(9) : 2012.
[5] Higgins JPT, Thomas J, Chandler J, et al.Cochrane handbook for systematic reviews of interventions version 6.0. cochrane[M]. Cochranet Raining, 2019.
[6] Nyaga VN, Arbyn M, Aerts M.Metaprop: a stata command to perform meta-analysis of binomial data[J]. Arch Public Health, 2014,72(1):39.
[7] WHO term set involved ADR system - organ retrieval codes[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2007, 4(3): 187-192.
[8] WHO adverse drug reaction glossary[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2007, 4(4): 250-256.
[9] WHO adverse drug reaction glossary[J]. Chinese Journal of Pharmaco-vigilance(中国药物警戒), 2007, 4(2): 123-128.
[10] WHO term set involved ADR system - organ code retrieves directory[J]. Chinese Journal of Pharmacovigilance(中国药物警戒), 2007, 4(1): 58-64.
[11] Zhou TH.Observation on the symptom and outcome of Lianhua Qingwen Capsule in the treatment of influenza[J]. Psychological Monthly(心理月刊), 2019, 14(11): 206.
[12] Wang SH, Liu JF, Zhang YL, et al.Systematic review of efficacy and safety of Lianhua Qingwen capsules in treatment of viral influenza[J]. Chinese Journal of Traditional Chinese Medicine(中国中药杂志), 2019, 44(7): 1503-1508.
[13] Cao WH.Meta-analysis of Lianhua Qingwen capsule and its basic research and clinical application[J]. Biped and Health(双足与保健), 2018, (17): 171-172.
[14] Zhu JH.Clinical application and research progress of Lianhua Qingwen preparation[J]. Strait Pharmaceutical Journal(海峡药学), 2019, 31(11): 200-202.
[15] Zhang LH, Xu FR, Sang WT, et al.Research of Lianhuaqingwen in treating influenza[J]. Pharmacy and Clinics of Chinese Materia Medica(中药与临床), 2019, 10(1): 54-58.
[16] Zhou Z, Wang SM, Liu YP.Meta-analysis of the efficacy and safety of Lianhua Qingwen capsule in the auxiliary treatment of community-acquired pneumonia[J]. China Medical Herald(中国医药导报), 2017, 14(33): 133-137.
[17] Zhang WB, Liu LN, Wang Z, et al.A meta-analysis of the efficacy and safety of Lianhua Qingwen combined with western medicine in the treatment of patients with common new coronary pneumonia[J]. Journal of Hainan Medical University(海南医学院学报), 2017, 14(33): 133-137.
[18] Zhang GQ.Study on the efficacy and adverse reactions of Radix Isatidis[J]. Journal of Sun Yat-sen University(中山大学学报), 2007, 27(8): 293-296.
[19] Wang YB, Zhang TM, Yang YM, et al.Research of therapeutic effect and safety of capluse Lianhuaqingwen on the virus cold[J]. Journal of Clinical Pulmonary Medicine(临床肺科杂志), 2008, 13(9): 1118-1119.
[20] Bai Y, Tan H.A case of gastrointestinal adverse reaction induced by Lianhuaqingwen capsules[J]. China Licensed Pharmacist Jan(中国执业药师), 2014, 11(1): 47-48.
[21] Huang ZH, Wang XH.Analysis of the effect of Lianhua Qingwen granule combined with ribavirin aerosol in the treatment of hand, foot and mouth disease in children[J]. Journal of Diseases Monitor & Control(疾病监测与控制), 2017, 11(3): 231-232.
[22] Liu L.Analysis of the efficacy and safety of Lianhua Qingwen granules in the treatment of viral influenza[J]. Healthmust-Readmagazine(健康必读), 2018, (28): 204.
[23] Cheng KJ, Wang H, Chen K.Advances in the research on the safety of menthol[J]. Liaoning Journal of Traditional Chinese Medicine(辽宁中医杂志), 2010, 37(2): 377-379.
[24] Kong YY.A case of skin rash caused by oral Lianhua Qingwen capsule[J]. Journal of New Medicine(新医学), 2010, 41(7): 433.
[25] Zhang Z.Analysis of adverse reactions and rational use of Houttuynia cordata[J]. Chinese Journal of Modern Drug Application(中国现代药物应用), 2009, 3(1): 135.
[26] Sun HR, Zhang L.Analysis on adverse reactions of combined drugs and promoting the rational use of drugs in clinic[J]. World Latest Medicine Information(世界最新医学信息文摘), 2019, 19(62): 252-253.